Abstract:Tumor microenvironment (TME) of a mature solid tumor is made of three components: tumor cell clusters or nests, stroma and immune cells. Most of the microvessels are located in the stroma, which is made of extracellular matrix and tumor associated fibroblasts (TAF). Circulating nanoparticles (NP) extravasating through the leaky microvessels first encounter the stroma and are taken up by TAF. SomeNPwill also penetrate through the stroma and reach tumor nests, depending on the particle size. In a stroma rich bladder cancer model, TAF are themajor cells taken up small LPC NP which contain ~80% cisplatin. Genome damaged TAF secrete Wnt16 which in a paracrine manner activates tumor cells for drug resistance and for epithelial-to-mesenchymal transition. It also induces neighboring naive fibroblast to become drug resistance and the endothelial cells to undergo angiogenesis. After repeated LPC administration, the bladder tumor becomes highlyWnt16 positive and highly drug resistant. Tumor rapidly regrows soon after LPC dosing is completed. Delivery of Wnt16 siRNA by LPH NP to the tumor can down-regulate Wnt16, inhibit the development of tumor drug resistance and enhance tumor growth inhibition by LPC. In advancedmurine B16F10melanoma, tumor does not contain a lot of stroma, and is relatively resistant to a nano-vaccine. LPH delivery of TGFβ siRNA, PLGA NP delivery of CDDO-Me (an anti-inflammatory) or Sunitinib (a broad-spectrum kinase inhibitor), or PEGylated curcumin micelles, can all downregulate the Th2 type cytokines, inhibit Treg cells and myeloid-derived suppressor cells and enhance tumor infiltrating CD8+ T-cells in the treated tumor. These immune modulators significantly enhance the tumor growth inhibition by a nano vaccine designed to boost the CTL response against the melanoma. Thus, we conclude that both siRNA and small molecule inhibitors can be delivered to modulate TME to facilitate either chemo or immune therapy, or both. Work supported by NIH grants CA149363, CA151652, CA149387 and DK100664.

Characterization and Functional Analysis of Tumor‐Derived Microparticles

Tumor-derived microparticles in tumor immunology and immunotherapy

The Potential Applications of Microparticles in the Diagnosis, Treatment, and Prognosis of Lung Cancer

Cellular Microparticles for Tumor Targeting Delivery: from Bench to Bedside

Microparticles: biogenesis, characteristics and intervention therapy for cancers in preclinical and clinical research

Tumor-derived microparticles-based nanomaterial as platform for delivery of tumor antigens to enhance immunogenicity

Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression

Tumor Cell-Derived Microparticles Polarize M2 Tumor-Associated Macrophages for Tumor Progression.

Mechanisms by Which Dendritic Cells Present Tumor Microparticle Antigens to CD8(+) T Cells

Cell-Free Tumor Microparticle Vaccines Stimulate Dendritic Cells Via Cgas/Sting Signaling

Delivery of Chemotherapeutic Drugs in Tumour Cell-Derived Microparticles

Tumour Microenvironment Responsive Nanoconstructs for Cancer Theranostic

Small Tumour Microparticle Enhances Drug Delivery Efficiency and Therapeutic Antitumour Efficacy

Research progress in circulating microparticles

Intratumoral Fate of Functional Nanoparticles in Response to Microenvironment Factor: Implications on Cancer Diagnosis and Therapy

Microfluidics analysis of cancer cell microenvironments and targeted destruction of cancer stem cells by nanomedicine

Nanoparticles targeting tumor-associated macrophages: A novel anti-tumor therapy

Research progress on microparticles and cancer

Roles of Microvesicles in Tumor Progression and Clinical Applications

Oral Delivery of Tumor Microparticle Vaccines Activates NOD2 Signaling Pathway in Ileac Epithelium Rendering Potent Antitumor T Cell Immunity.

Isolation and Characterization of Small Extracellular Vesicles from Murine Primary Mammary Tumor